The EU’s research commissioner appears to have cited a widely discredited and possibly fabricated study in a speech extolling the benefits of AI in science. Ekaterina Zaharieva has made deploying AI ...

Ganesh Sai Kopparthi is reshaping research culture with integrity, open dialogue, and responsible innovation in scholarship, peer review, and science.

Writing essays takes a ton of time - to say nothing of all the extra time you spend in the research phase, as well as editing each draft to make sure you didn't make any typos or accidentally paste in ...

This paper aims to use this boundary conflict as an entry point to reflect upon two major issues. First, we intend to use the eruption of the dispute between Bari and Mundari to analyze and ...

The group of outside experts will also consider shot ingredients like aluminum as well as the timing and order of shots, according to a document posted on the agency’s website.

Restaurant payroll remains one of the most time-consuming and error-prone aspects of operations, according to The Restaurant Payroll Benchmark: A Framework for Growth, a new industry study released by ...

Shares of companies outside of China that produce rare earths and minerals surged Thursday as the country moved to tighten exports.

Except for one key aspect, the setup is a familiar one in medicine: An expert diagnostician presents a particularly challenging case to a roomful of colleagues, carefully walking them through the ...

Africa’s “leaders for life” are easy to mock. Mr Biya sometimes runs his country from the Intercontinental Hotel in Geneva. Mr Obiang has appointed as vice-president his son, a money-launderer with a ...

As U.S. President Donald Trump dreams of receiving the 2025 Nobel Peace Prize, his track record as a peacemaker in the world's largest ongoing war remains questionable. Despite high-profile meetings ...

Oxford University has been world number one in the Times Higher Education World University Rankings since 2017 - the longest time any university has ...

CorMedix surged 59% since March, driven by strong DefenCath sales and its acquisition of Melinta Therapeutics, diversifying its portfolio. DefenCath's robust Q1 and Q2 sell-in exceeded expectations, ...